Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 838 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer, MET Alteration
Interventions: ANS014004 + PLB1004, ANS014004 + Osimertinib; Drug
Lead sponsor: Beijing Pearl Biotechnology Limited Liability Company; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer Metastatic, EGFR Gene Mutation
Interventions: Osimertinib, Alisertib; Drug
Lead sponsor: Collin Blakely; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Conditions: Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions: A166; Drug
Lead sponsor: Klus Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more

Conditions: Advanced Solid Tumor
Interventions: Drug: BG-T187, Other Therapeutic Agents; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Hackensack, New Jersey • Houston, Texas • Fairfax, Virginia + 1 more

Conditions: Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation, Healthy Volunteers
Interventions: BAY2927088, Midazolam; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
Interventions: Osimertinib, Ramucirumab; Drug
Lead sponsor: Xiuning Le; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 7 more

Conditions: ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Nivolumab, Plinabulin; Biological · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Glioblastoma Multiforme
Interventions: Steroid eye drops, Vasoconstrictor eye drops, Cold compress, Ophthalmic steroid ointment, Depatuxizumab mafodotin, Temozolomide, Radiation; Drug · Other · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Chronic Kidney Disease
Interventions: Immediate release sodium nitrite, Isoquercetin, placebos; Drug · Dietary Supplement · Other
Lead sponsor: Tulane University; Other
Eligibility: 21 Years to 74 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
Interventions: CK-101; Drug
Lead sponsor: Checkpoint Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Sarasota, Florida • St Louis, Missouri • Hackensack, New Jersey + 1 more

Conditions: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma, Glioblastoma Multiforme
Interventions: ABBV-221; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
Interventions: HWK-007; Drug
Lead sponsor: Whitehawk Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more

Conditions: Colorectal Cancer
Interventions: cetuximab, Irinotecan; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 116
States / cities: Tucson, Arizona • Pine Bluff, Arkansas • Bakersfield, California + 104 more

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions: T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Orange, California + 10 more

Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
Interventions: Paclitaxel, Alisertib; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Including Dallas and Austin, Texas

Conditions: Non Small Cell Lung Cancer
Interventions: osimertinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Durham, North Carolina • Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Eribulin Mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Denver, Colorado • Columbia, Maryland • Omaha, Nebraska + 8 more

Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: TAK-228, Tamoxifen; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Metabolic Acidosis, Chronic Kidney Disease
Interventions: TRC101, Placebo; Drug
Lead sponsor: Tricida, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 20
States / cities: Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel; Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 19
States / cities: Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more

Search by objective public record fields.

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

UNITE Study: Understanding New Interventions With GBM ThErapy

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

PALbociclib CoLlaborative Adjuvant Study

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2